Derma Sciences

Derma Sciences is a Medical Devices company specializing in the field of Advanced Wound Care. Currently their major products are Medihoney, Algicell AG, Xtrasorb wound dressing, Bioguard and Mobility1. Their newest product DSC127 - an Angiotensin Analog - is currently in Phase II Pre-Clinical trials.
Company Growth (employees)
Type
Public
HQ
Princeton, US
Size (employees)
260 (est)
Derma Sciences is headquartered in Princeton, US

Key People at Derma Sciences

Edward J. Quilty

Edward J. Quilty

Chairman & CEO
John E. Yetter

John E. Yetter

CFO & Vice President of Finance
Srini Conjeevaram

Srini Conjeevaram

Director

Derma Sciences Office Locations

Derma Sciences has offices in Princeton, New York
Princeton, US
New York, US

Derma Sciences Metrics

Derma Sciences Summary

Market capitalization

$197.9 m

Closing share price

$7
Derma Sciences's current market capitalization is $197.9 m.

Derma Sciences Financials

Derma Sciences's revenue is $84.5 m in FY, 2015 which is a 0.9% increase from the previous period.
FY, 2014FY, 2015

Revenue

$83.7 m$84.5 m

Revenue growth, %

0.9%

Gross profit

$30.1 m$32.7 m

Operating expense total

$70.2 m$54.7 m

EBIT

($40.1 m)($22 m)

Net Income

($39.8 m)($38.1 m)

Operating cash flow

$12.9 m($3.6 m)

Derma Sciences Market Value History

Derma Sciences Online Presence

Derma Sciences News

Derma Sciences Company Life

You may also be interested in